Valion Bio, Inc. earnings releases VBIO

Annual Quarterly

Valion Bio, Inc. last reported quarterly results on May 14, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026). It usually reports 44–45 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
May 14, 2026 44 days after quarter end	Q1 FY2026 ended Mar 31, 2026	—	-6 -312.9%	—
Nov 14, 2025 45 days after quarter end	Q3 FY2025 ended Sep 30, 2025	0 +15.9%	-3 -81.4%	—
Aug 14, 2025 45 days after quarter end	Q2 FY2025 ended Jun 30, 2025	0 -38.6%	-2 -52.5%	-2.19 +59.2%
May 15, 2025 45 days after quarter end	Q1 FY2025 ended Mar 31, 2025	0 -79.0%	-2 -1.4%	-2.52 +85.3%
Nov 14, 2024 45 days after quarter end	Q3 FY2024 ended Sep 30, 2024	0 -55.3%	-1 +18.7%	-0.23 +84.5%
Aug 14, 2024 45 days after quarter end	— ended Jun 30, 2024	—	—	—
Nov 14, 2023 45 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 14, 2023 45 days after quarter end	— ended Jun 30, 2023	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: VBIO (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: San Antonio, TX
SEC filer status: , Emerging growth company
SEC CIK: 1787740
Former names: Tivic Health Systems, Inc. (until Apr 23, 2026)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.